Don't want ads? Subscribe or login now.

Cytokinetics Investor Sues Over Heart Drug Approval Claims

By Katryna Perera · September 18, 2025, 8:50 PM EDT

Biopharmaceutical company Cytokinetics and its CEO have been hit with a proposed investor class action in California federal court alleging they made false and misleading statements about the regulatory timeline for...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Seidman v. Cytokinetics, Incorporated et al

Case Number

3:25-cv-07923

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

September 17, 2025

Recent Articles By Katryna

October 17, 2025
Acadia Investors Score Partial Win In Fraud Class Action
September 08, 2025
FibroGen To Pay SEC $1.25M Over Drug Mistatements
September 05, 2025
Vein Tech Maker Wants Suit Over DOJ Kickback Probe Tossed
August 28, 2025
2nd Circ. Affirms Hedge Fund Win In $87M Short-Swing Suit
August 28, 2025
Kimberly-Clark To Pay $40M Over Adulterated Surgical Gowns
August 20, 2025
Ohio Justices Free Bank From $77M Guaranty Disclosure Duty
August 19, 2025
Sotera Urges 6th Circ. To Toss Investors' Toxic Gas Suit
August 11, 2025
Judge OKs Becton Dickinson's $9M Investor Settlement
August 07, 2025
BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd
August 06, 2025
Indivior Beats Investor Suit Over Opioid Drug Sales Forecasts